Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Evofem Biosciences Is Soaring Today

TheMotleyFool

0 0

Why Evofem Biosciences Is Soaring TodayPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

In response to its posting positive results from a midstage clinical trial, shares of Evofem Biosciences (NASDAQ: EVFM), a clinical-stage biotech focused on women's sexual and reproductive health, had risen 13% as of 11:27 a.m. EST on Monday.

Evofem reported top-line results from its phase 2b AMPREVENCE trial, which was designed to test the efficacy and safety of its lead product candidate Amphora as a preventive treatment for urogenital chlamydia and gonorrhea in women.

Here are the key takeaways from the four-month study release:

Source Fool.com

Like: 0

EVFM

Share